DE69623970D1 - Formulierung von d-threo methylphenidat mit verzögerter freisetzung - Google Patents

Formulierung von d-threo methylphenidat mit verzögerter freisetzung

Info

Publication number
DE69623970D1
DE69623970D1 DE69623970T DE69623970T DE69623970D1 DE 69623970 D1 DE69623970 D1 DE 69623970D1 DE 69623970 T DE69623970 T DE 69623970T DE 69623970 T DE69623970 T DE 69623970T DE 69623970 D1 DE69623970 D1 DE 69623970D1
Authority
DE
Germany
Prior art keywords
formulation
delayed release
threo methylphenidate
threo
methylphenidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623970T
Other languages
English (en)
Other versions
DE69623970T2 (de
Inventor
Frances Baker
Clive Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Application granted granted Critical
Publication of DE69623970D1 publication Critical patent/DE69623970D1/de
Publication of DE69623970T2 publication Critical patent/DE69623970T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
DE69623970T 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung Expired - Lifetime DE69623970T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation
PCT/GB1996/001690 WO1997003673A1 (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate

Publications (2)

Publication Number Publication Date
DE69623970D1 true DE69623970D1 (de) 2002-10-31
DE69623970T2 DE69623970T2 (de) 2003-06-05

Family

ID=10777685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623970T Expired - Lifetime DE69623970T2 (de) 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung

Country Status (17)

Country Link
US (1) US5874090A (de)
EP (1) EP0841928B1 (de)
JP (1) JPH11509228A (de)
KR (1) KR100481416B1 (de)
AT (1) ATE224715T1 (de)
AU (1) AU702371B2 (de)
CA (1) CA2223643C (de)
CZ (1) CZ285956B6 (de)
DE (1) DE69623970T2 (de)
DK (1) DK0841928T3 (de)
ES (1) ES2186790T3 (de)
GB (1) GB9514451D0 (de)
HU (1) HU224314B1 (de)
MX (1) MX9800394A (de)
PT (1) PT841928E (de)
SK (1) SK281569B6 (de)
WO (1) WO1997003673A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
JPH11509226A (ja) 1995-07-14 1999-08-17 メデバ・ユアラプ・リミテッド Ｄ−トレオ−メチルフェニデートおよびもうひとつの医薬を含む組成物
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP4613275B2 (ja) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
JP2002541093A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド ｄ−ｔｈｒｅｏ−メチルフェニデートおよび第２のＣＮＳ刺激薬のパルス性送達のための薬学的投薬形態
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
EP2269587A1 (de) 1999-10-29 2011-01-05 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP3856283B2 (ja) * 2000-02-14 2006-12-13 シャープ株式会社 固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
EP1163907B1 (de) * 2000-06-17 2006-04-12 Pharmaquest Limited Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6638533B2 (en) 2002-01-03 2003-10-28 George Krsek Pulse dosage formulations of methylphenidate and method to prepare same
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
BRPI0517166A (pt) * 2004-12-09 2008-09-30 Celgene Corp uso de d-treo-metilfenidato ou um sal do mesmo
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK2688557T3 (da) 2011-03-23 2017-11-27 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
KR102174787B1 (ko) 2018-11-14 2020-11-05 호서대학교 산학협력단 재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) * 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
KR19990028984A (ko) 1999-04-15
CA2223643A1 (en) 1997-02-06
ATE224715T1 (de) 2002-10-15
SK281569B6 (sk) 2001-05-10
JPH11509228A (ja) 1999-08-17
DE69623970T2 (de) 2003-06-05
EP0841928B1 (de) 2002-09-25
US5874090A (en) 1999-02-23
HUP9802252A2 (hu) 1999-01-28
SK2998A3 (en) 1998-07-08
HUP9802252A3 (en) 1999-04-28
KR100481416B1 (ko) 2005-07-29
ES2186790T3 (es) 2003-05-16
HU224314B1 (hu) 2005-07-28
CA2223643C (en) 2003-12-23
PT841928E (pt) 2002-12-31
WO1997003673A1 (en) 1997-02-06
MX9800394A (es) 1998-09-30
DK0841928T3 (da) 2003-01-27
CZ9298A3 (cs) 1998-06-17
AU6466196A (en) 1997-02-18
EP0841928A1 (de) 1998-05-20
AU702371B2 (en) 1999-02-18
CZ285956B6 (cs) 1999-12-15
GB9514451D0 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
DE69623970T2 (de) Formulierung von d-threo methylphenidat mit verzögerter freisetzung
DE3864608D1 (de) Hmg-coa-reduktasehemmer.
DE68907909T2 (de) Präparat zur behandlung von erektionsstörungen.
DE68909424D1 (de) Verfahren zum kontrollieren der oberflaechenblaehung von fabrizierten imbissprodukten.
MX9705005A (es) Inhibidores de la proteina de transferencia de trigliceridos microsomicos y metodo.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE69007223T2 (de) Verfahren und zusammensetzung von geprägten schuhsohlen.
KR900700420A (ko) 2,3-디플루오로벤젠의 제조방법
ATE174895T1 (de) Aromatische inhibitoren von acetylcholinesterase
DE69710051T2 (de) Auflösungsverfahren von threo-methylphenidate
DE3869590D1 (de) Mischung zur behandlung von hypercholesterolemie.
NO992296D0 (no) FremgangsmÕte for disubstituerte pyridiner
DE3887474T2 (de) Verfahren zum Methylieren von 2,2,6,6-Tetramethylpiperidin enthaltenden Triazinverbindungen.
DE59604829D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin
DE69230224T2 (de) Potenzierung von nmda-antagonisten
DE68915387D1 (de) Verfahren zur Herstellung von ethylenischen Pfropfcopolymeren.
DE68903208T2 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE59310153D1 (de) Verfahren zur Herstellung von 4-Hydroxy-2.2.6.6-tetramethylpiperidin
DE69625069D1 (de) Insektizide von n-(substituiertes arylmethyl)-4-(bis (substituiertes phenyl oder pyridyl)methyl)-piperidin.
DE69013964D1 (de) Verfahren zum Verbinden von flachen Leistungskabeln.
DE69031965D1 (de) System zum Durchgang von Hilfsmittelinformation
DE3781272T2 (de) Verfahren zum elektromagnetischen Abschirmen von Gebäuden.
DE59809538D1 (de) Verfahren zur Herstellung von 1,2,3,6-Tetrahydro-2,2,6,6-tetramethylpyridin
NO903496D0 (no) Fremgangsmaate for metanomdanning.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition